|Bid||9.24 x 800|
|Ask||9.43 x 1100|
|Day's Range||9.22 - 9.78|
|52 Week Range||6.26 - 43.90|
|Beta (5Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.13|
Puma Biotechnology presented interim results of its CONTROL Trial on Dec. 13 at the 2019 San Antonio Breast Cancer Symposium.
Puma announced its collaborators at The Institute of Cancer Research presented results from the plasmaMATCH Trial in patients treated with neratinib
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
Puma Biotechnology presented results from its ongoing SUMMIT "basket" trial in a poster at the 2019 San Antonio Breast Cancer Symposium.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia has received marketing approval of NERLYNX® in Singapore from the Health Sciences Authority , a statutory board under the Ministry of Health of the Singapore Government.
Last name of Chief Executive Officer of Pierre Fabre Pharmaceuticals in fourth paragraph should read: Lowinski .
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.11% and -7.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019 compared to the third quarter 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
Puma Biotechnology, Inc. announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX® for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who have completed adjuvant trastuzumab-based therapy ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
Alan Auerbach became the CEO of Puma Biotechnology, Inc. (NASDAQ:PBYI) in 2011. First, this article will compare CEO...
Belying the popular notion that oncology biotechs are lucrative investment options,Goldman Sachs is taking a bearish stance on Puma Biotechnology Inc (NASDAQ: PBYI ) and Clovis Oncology Inc (NASDAQ: CLVS ...